|
|
Vaccine Detail
|
TRP-2: 180-188 Peptide Vaccine |
| Vaccine Information |
- Vaccine Name: TRP-2: 180-188 Peptide Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007115
- Type: Peptide vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- TRP-2
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- Preparation: The peptides were then synthesized by Fmoc chemistry and purified by HPLC to a purity of > 95%. Lyophilized peptides were dissolved in DMSO at a concentration of 20 mg/ml and stored at -70°C (Tang et al., 2007).
- Description: This is for Melanoma Cancer (NCT00022438). A recombinant peptide consisting of amino acid residues 180 to 188 of the tyrosinase-related protein 2 (TRP2). Expressed by cells of melanocyte origin, TRP2 is an enzyme involved in the process that converts tyrosinase to melanin pigments. Vaccination with TRP-2: 180-188 peptide may induce cytotoxic T lymphocyte (CTL) responses to melanoma cells (NCI04) (NCIT_C2815). TRP-2 can express on primary tumor cell lines derived from patients with glioblastoma multiforme (Tang et al., 2007).
|
| Host Response |
|
|
| References |
NCIT_C2815: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2815]
NCT00022438: [https://clinicaltrials.gov/show/NCT00022438/]
Tang et al., 2007: Tang Y, Lin Z, Ni B, Wei J, Han J, Wang H, Wu Y. An altered peptide ligand for naïve cytotoxic T lymphocyte epitope of TRP-2(180-188) enhanced immunogenicity. Cancer immunology, immunotherapy : CII. 2007; 56(3); 319-329. [PubMed: 16906394].
|
|
